Impact of Cytokine Inhibitor Therapy on the Prevalence, Seroconversion Rate, and Longevity of the Humoral Immune Response Against SARS-CoV-2 in an Unvaccinated Cohort.
David SimonKoray TascilarArnd KleyerFilippo FagniGerhard KrönkeChristine MederPeter DietrichTill OrlemannThorsten KliemJohanna MößnerAnna-Maria LiphardtVerena SchönauDaniela BohrLouis SchusterFabian HartmannMoritz LeppkesAndreas RammingMilena PachowskyFlorian SchuchMonika RonnebergerStefan KleinertAxel J HueberKarin MangerBernhard MangerRaja AtreyaCarola BerkingMichael SticherlingMarkus F NeurathLarissa Valor-MéndezPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2022)
IMID patients treated with bDMARDs have a lower prevalence of SARS-CoV-2 antibodies, seroconvert less frequently after SARS-CoV-2 infection, and may exhibit a reduced longevity of their humoral immune response.